BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vi C, Mandarano G, Shigdar S. Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach. Int J Mol Sci 2021;22:6163. [PMID: 34200484 DOI: 10.3390/ijms22116163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tran LH, Graulus GJ, Vincke C, Smiejkowska N, Kindt A, Devoogdt N, Muyldermans S, Adriaensens P, Guedens W. Nanobodies for the Early Detection of Ovarian Cancer. Int J Mol Sci 2022;23. [PMID: 36430166 DOI: 10.3390/ijms232213687] [Reference Citation Analysis]
2 Malatesta M. Molecular Imaging in Nanomedical Research 2.0. IJMS 2022;23:13011. [DOI: 10.3390/ijms232113011] [Reference Citation Analysis]
3 Ebrahimi F, Noaparast Z, Abedi SM, Hosseinimehr SJ. Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging. Med Oncol 2022;39:204. [PMID: 36175805 DOI: 10.1007/s12032-022-01798-6] [Reference Citation Analysis]
4 Nakhjavani M, Shigdar S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol Res 2021;175:106019. [PMID: 34861397 DOI: 10.1016/j.phrs.2021.106019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Youssef A, Haskali MB, Gorringe KL. The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic. Cancers (Basel) 2021;13:5596. [PMID: 34830751 DOI: 10.3390/cancers13225596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]